• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

    0.9541 +0.0741 (+8.42%)
    Delayed Quote Updated: 3:04 PM EDT, Oct 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Pliant Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
    Selected for oral presentation at Clinical Trials Mini Symposium 
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Update on BEACON-IPF
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.